bpc-157 canada legal status Public advisory Peptide BPC-157 - Does It
Description
Petratos S, Gonzales MF, Azari MF, Marriott M, Minichiello R a, Shipham K a, et al
A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: Mitochondrial agents, N-acetylcysteine, and placebo
Both are used based on strong preclinical evidence, favorable safety data, and growing clinical experience
The drugmaker says patients typically start a dose of 0.25 mg once weekly for four weeks before upping the dose in intervals, reaching 2.4 mg
Earlier-stage research and a narrower use case
5mg10mg
